Skip to main content
. 2012 Jul 12;107(4):598–603. doi: 10.1038/bjc.2012.304

Table 4. Antitumour activity.

  Aflibercept, 4 mg kg−1, n=6 Aflibercept, 5 mg kg−1, n=7 Aflibercept, 6 mg kg−1, n=17 All patients, n=30
Best overall response, n (%)
 Partial response 1 (16.7) 0 4 (23.5) 5 (16.7)
 Stable disease 4 (66.7) 7 (100.0) 7 (41.2) 18 (60.0)
 Progressive disease 0 0 6 (35.3) 6 (20.0)
 Not evaluable 1 (16.7) 0 0 1 (3.3)
         
Patients with stable disease for >3 months, n (%) 3 (50.0) 3 (42.9) 4 (23.5) 10 (33.3)